Dean's Advisory Council: Elizabeth A. Mily

Elizabeth Mily is Managing Director in Healthcare Investment Banking at Barclays Capital. She leads the Life Science Tools, Diagnostics and Pharma Outsourcing sectors and covers selected large pharmaceutical companies.

Ms. Mily has 21 years of experience in investment banking and M&A, predominantly in the healthcare sector. She has executed over $165 billion in completed advisory assignments during her career and has advised on more than $7.5bn in equity and equity-linked financings. Some of her most notable client advisory assignments include: the $87 billion merger of Glaxo Wellcome and Smithkline Beecham, the $37 billion merger of Astra A/S and Zeneca Plc, the proposed and subsequently withdrawn $22 billion acquisition of Guidant by Johnson & Johnson, the $17 billion acquisition of Pfizer’s Consumer Healthcare Business by Johnson & Johnson, the $4.1bn acquisition of J&J’s Ortho Clinical Diagnostics by Carlyle, the $4 billion raid defense and sale of Ventana Medical to Roche Holdings, the $2 billion merger of Nycomed and Amersham, the $1.7bn defense and sale of Biosite to Inverness Medical, the $1.6 billion acquisition of Digene by QIAGEN, the $1.5 billion sale of Inveresk Research to Charles River Labs, the $1.5 billion IPO of IMS, the $1.1 billion merger of Allscripts and Misys healthcare and the $1billion IPO and subsequent follow-on for Quintiles. Ms. Mily also advised on equity/equity-linked transactions for Alcon Labs, Allscripts, Express Scripts, ICON Plc, Illumina, Inveresk Research, Liposcience, Lundbeck, Millipore and QIAGEN. Other advisory clients include: Abbott Labs, Alcon Labs, ATMI, Baxter, Beckman Coulter, Becton Dickinson, CuraGen Corporation, GlaxoSmithKline, GE Healthcare, MDS, Novartis, Procter & Gamble, Techne Corporation and Waters.

Ms. Mily joined Barclays Capital in 2010, serving as the Chief Operating Officer of Global Mergers & Acquisitions for two years before moving to the Global Healthcare group as a senior coverage officer. Prior to joining Barclays, Ms. Mily served as Senior Vice President for Corporate Strategy and Development at Thermo Fisher Scientific Corporation. Prior to that she spent 16 years at Goldman, Sachs & Co. where she was a Managing Director and senior coverage officer within the Healthcare Department of the Investment Banking Division. Ms. Mily began her professional career with Goldman Sachs in Frankfurt, Germany and subsequently worked in London (four years) and New York (ten years).

Ms. Mily was awarded a Master of Science in Foreign Service, summa cum laude, from Georgetown University. She was a Fulbright Scholar to the Universities of Cologne and Hamburg, Germany. Ms. Mily received a Bachelor of Arts in German Literature and European History, with honors and distinction, from The Ohio State University